R&D Scientist 1

4bases is happy to announce a collaboration agreement with Meridian Bioscience. Ambient-stable NGS workflows, enabled by Meridian's lyophilization expertise, expand global access to 4bases' KaryoSolver(TM), a platform for rapid structural variant analysis. The Life Science division of Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, today announced a collaboration with 4bases SA focused on one critical objective: expanding the accessible market and enhancing the global deployment of KaryoSolver(TM), a next-generation cytogenetics assay, through advanced assay stabilization. KaryoSolver(TM) represents a significant step forward in cytogenetics. Traditional workflows rely on multiple complementary tests, often taking days to deliver a complete picture. In contrast, KaryoSolver(TM) consolidates structural variant detection into a single assay with integrated data analysis, providing actionable genomic insights within hours. However, bringing this innovation to a global market requires overcoming a critical barrier: reagent stability. Conventional liquid-based NGS library preparation solutions are inherently limited by short shelf life, creating significant challenges across the distribution chain, including the cost and complexity of refrigerated shipping and storage that have historically restricted scalable global expansion. Meridian addressed this challenge through its advanced reagent stabilization platform, combining formulation science with optimized enzyme lyophilization technology. By stabilizing the NGS library preparation components, Meridian enabled KaryoSolver(TM) to be shipped and stored at ambient temperatures, eliminating cold-chain requirements, extending shelf life, and simplifying inventory management across the global distribution channels. In addition, lyophilization streamlines manufacturing, supporting more efficient and scalable production. "Our platform technology enabled the transition of the assay into a room-temperature stable format while preserving the performance characteristics required for molecular diagnostics," said Florent Chang-Pi-Hin, Vice President, Research and Development at Meridian Life Science. "By removing cold-chain constraints without sacrificing assay integrity, we're helping expand access to reliable testing worldwide." In this fruitful collaboration, Meridian and 4bases R&D teams joined efforts to optimize Meridian's Lyophilized NGS Enzymatic DNA Fragmentation reagents for the development of a kit to be integratied into 4bases' Oxford Nanopore Technologies workflow, ensuring reliable and efficient sample preparation within the broader assay system. "The idea behind KaryoSolver(TM) is to simplify access to comprehensive genetic diagnosis, and Meridian's expertise in stabilization has been transformative," said Fabio Grandi, COO & Co-Founder at 4bases. "Short shelf life and cold-chain requirements previously limited how far and how efficiently we could scale. With lyophilization, we can now reliably supply our global customers while simplifying logistics, reducing costs, and accelerating the adoption of KaryoSolver(TM) as a rapid, single-workflow solution for cytogenetics." Together, Meridian and 4bases are removing key barriers to advanced genomic testing, pairing breakthrough assay design with the stability, scalability, and operational efficiency required for effective global deployment. 4bases and Meridian Bioscience will both be exhibiting at the upcoming European Human Genetics Conference (ESHG) on June 13-16 in Gothenburg, Sweden, where attendees will have the possibility to learn more about the companies' collaboration and latest advances in ambient-stable next-generation sequencing workflows and cytogenetics solutions. Additional event details, including opportunities to schedule meetings with the Meridian Bioscience and 4bases teams during ESHG, can be found at https://4bases.ch and Meridian Bioscience's events page. Share:

Excited to announce a strategic investment in heva — an AI-powered platform transforming cross-border healthcare access! ✈️🌍 India is a premier destination for medical tourism, and heva, founded by Varun & Hector is solving the fragmentation that limits its growth. To healthcare providers: heva helps you focus on delivering world-class care — while they connect you to patients globally. | 15 comments on LinkedIn

CINCINNATI, March 6, 2025 /PRNewswire/ -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, proudly congratulates Catherine Lufkin, Senior Director, Global Point of Care, on being honored with Pure Earth's 2025 "Force of Nature" Award. This prestigious recognition celebrates her leadership and dedication to advancing environmental health, particularly in the fight against lead poisoning.Lufkin is being recognized at Pure Earth's International Women's Day celebration for her unwavering commitment to ensuring access to fast, accurate blood lead testing in communities impacted by lead contamination. Her leadership has been instrumental in Meridian's partnership with Pure Earth, which has provided LeadCare® II blood lead testing technology to under-resourced communities worldwide since 2016. Her dedication to advancing lead testing was also a driving force behind Meridian winning the CDC's Lead Detect Prize, a prestigious competition that fostered the development of innovative, rapid lead detection technologies to enhance public health efforts."We are immensely proud of Catherine's achievements and this well-deserved recognition," said Tony Serafini-Lamanna, President of Meridian Bioscience Diagnostics. "Her work exemplifies our mission to improve global health through innovation and collaboration. In our ongoing partnership with Pure Earth, we remain committed to reducing lead exposure and its harmful effects on vulnerable populations."The LeadCare II system, the only CLIA-waived point-of-care blood lead testing system, is a vital tool in Pure Earth's global efforts to combat lead poisoning